Ewing Sarcoma
Conditions
Brief summary
The primary end point for all randomisations is Event-free survival, defined as the time from randomisation until first failure event
Detailed description
Randomisation A: Induction chemotherapy Overall Survival, Toxicity, Cancer Quality of Life Measures, Histological response (if surgery is performed), Randomisations B1 & B2: Radiotherapy Local Failure-Free Survival Time, Overall Survival, Toxicity, Achievement of local control, Acute post-radiotherapy toxicity, Late toxicity, Cancer Quality of Life Measures, Randomisation C: Maintenance therapy Overall Survival, Toxicity, Cancer Quality of Life Measures
Interventions
DRUGVINORELBINE
DRUGCYCLOPHOSPHAMIDE
Sponsors
The University Of Birmingham
Eligibility
Sex/Gender
All
Age
0 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end point for all randomisations is Event-free survival, defined as the time from randomisation until first failure event | — |
Secondary
| Measure | Time frame |
|---|---|
| Randomisation A: Induction chemotherapy Overall Survival, Toxicity, Cancer Quality of Life Measures, Histological response (if surgery is performed), Randomisations B1 & B2: Radiotherapy Local Failure-Free Survival Time, Overall Survival, Toxicity, Achievement of local control, Acute post-radiotherapy toxicity, Late toxicity, Cancer Quality of Life Measures, Randomisation C: Maintenance therapy Overall Survival, Toxicity, Cancer Quality of Life Measures | — |
Countries
Denmark, France, Netherlands, Norway, Spain
Outcome results
None listed